Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.